Aristotle Capital Management LLC boosted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,279,468 shares of the medical research company’s stock after purchasing an additional 86,378 shares during the period. Amgen makes up about 2.6% of Aristotle Capital Management LLC’s portfolio, making the stock its 10th biggest position. Aristotle Capital Management LLC owned approximately 0.34% of Amgen worth $388,604,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Ancora Advisors LLC purchased a new stake in shares of Amgen in the 1st quarter valued at $3,520,000. Pennsylvania Trust Co boosted its holdings in shares of Amgen by 1.0% in the 4th quarter. Pennsylvania Trust Co now owns 97,619 shares of the medical research company’s stock valued at $16,976,000 after acquiring an additional 1,003 shares during the last quarter. Kings Point Capital Management boosted its holdings in shares of Amgen by 10.3% in the 4th quarter. Kings Point Capital Management now owns 17,637 shares of the medical research company’s stock valued at $3,067,000 after acquiring an additional 1,653 shares during the last quarter. Modera Wealth Management LLC boosted its holdings in shares of Amgen by 1.3% in the 4th quarter. Modera Wealth Management LLC now owns 26,252 shares of the medical research company’s stock valued at $4,565,000 after acquiring an additional 331 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC boosted its holdings in shares of Amgen by 18.6% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 43,099 shares of the medical research company’s stock valued at $7,495,000 after acquiring an additional 6,753 shares during the last quarter. 78.27% of the stock is currently owned by institutional investors.

Amgen opened at $183.95 on Tuesday, according to Marketbeat.com. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 2.14. The firm has a market capitalization of $122.42 billion, a P/E ratio of 14.62, a PEG ratio of 2.30 and a beta of 1.38. Amgen, Inc. has a 1 year low of $162.69 and a 1 year high of $201.23.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, April 24th. The medical research company reported $3.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.24 by $0.23. The company had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.44 billion. Amgen had a net margin of 9.67% and a return on equity of 35.80%. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $3.15 earnings per share. equities research analysts forecast that Amgen, Inc. will post 13.63 earnings per share for the current fiscal year.

Several analysts have recently commented on AMGN shares. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $194.00 price objective on the stock in a report on Thursday, April 5th. TheStreet downgraded shares of Amgen from a “b-” rating to a “c+” rating in a report on Wednesday, April 11th. BidaskClub downgraded shares of Amgen from a “hold” rating to a “sell” rating in a report on Saturday, March 24th. Vetr downgraded shares of Amgen from a “hold” rating to a “sell” rating and set a $181.60 price objective on the stock. in a report on Tuesday, March 6th. Finally, Royal Bank of Canada dropped their price objective on shares of Amgen to $183.00 and set a “sector perform” rating on the stock in a report on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $193.08.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Monday, May 14th. The shares were sold at an average price of $174.10, for a total transaction of $265,502.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 4,575 shares of company stock valued at $809,851 over the last 90 days. 0.27% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.